Charles River Laboratories International (CRL) has been the subject of multiple pivotal events. A downgrading to a
Hold rating by
Wall Street Zen has been noted, alongside
share price momentum and the scheduling of the company's
Fourth-Quarter 2025 Earnings as well as the
2026 Guidance Release. There has been an initiation of an investigation into the company's officers and directors by
Kahn Swick & Foti, LLC. CRL has also drawn attention for
acquiring a Cambodia-based monkey supplier for $510 million, entering a
manufacturing collaboration with Gazi University, and receiving a moderate buy recommendation from market analysts. Moreover,
CEO transition plans have taken shape, increasing their stock's valuation. There is also positive investor interest, with
Rakuten Investment Management Inc. and Nordea Investment Management AB buying significant shares. Notably, there's been a consistent strengthening of their
DSA bookings trend. The retirement of
CEO Jim Foster in 2026 and the expected succession by
Birgit Girshick has generated considerable reaction. Some concerns are raised on the company's stock underperforming the Nasdaq, amid strategic overhauls and buyback plans.
Charles River Laboratories International CRL News Analytics from Fri, 11 Apr 2025 07:00:00 GMT to Sat, 24 Jan 2026 05:48:31 GMT -
Rating 4
- Innovation 3
- Information 8
- Rumor 3
